CliffBio
small molecule

EXKIVITY

MOBOCERTINIB SUCCINATE

Loss of exclusivityMay 2035latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameEXKIVITY
Active ingredientMOBOCERTINIB SUCCINATE
StrengthEQ 40MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2021
Marketing statusDISCN

Listed patents

PatentExpiresType
10227342May 2035substance, product
9796712May 2035substance, product

Regulatory exclusivity

CodeExpires
ODE-374September 2028
NCESeptember 2026

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.